
Ricarda Herr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7835828/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nature Communications, 2016, 7, 10498.	12.8	273
2	Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 763-774.	7.7	211
3	Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Molecular Systems Biology, 2011, 7, 489.	7.2	172
4	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	7.8	110
5	Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget, 2017, 8, 42901-42916.	1.8	60
6	Discrete cytosolic macromolecular <scp>BRAF</scp> complexes exhibit distinct activities and composition. EMBO Journal, 2017, 36, 646-663.	7.8	52
7	B-Raf Inhibitors Induce Epithelial Differentiation in <i>BRAF</i> -Mutant Colorectal Cancer Cells. Cancer Research, 2015, 75, 216-229.	0.9	43
8	BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene, 2018, 37, 1576-1593.	5.9	37
9	A novel MCF-10A line allowing conditional oncogene expression in 3D culture. Cell Communication and Signaling, 2011, 9, 17.	6.5	34
10	EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. PLoS ONE, 2014, 9, e107165.	2.5	27
11	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Oncotarget, 2016, 7, 26628-26652.	1.8	25
12	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene, 2020, 39, 814-832.	5.9	19
13	BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. Oncogene, 2020, 39, 6053-6070.	5.9	19
14	BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?. Molecular and Cellular Oncology, 2015, 2, e1002709.	0.7	5
15	Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. Genomics Data, 2015, 4, 158-161.	1.3	2